Carolina Salgado Pedace
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolina Salgado Pedace has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Erica Chimara
Instituto Adolfo Lutz
2 shared publications - Andreia Rodrigues de Souza
Bacteriology Center, Adolfo Lutz Institute, São Paulo/SP, Brazil
1 shared publication Andréia Rodrigues Souza
Tuberculosis and Mycobacteriosis Branch, Bacteriology Center, Adolfo Lutz Institute, Avenida Doutor Arnaldo, 351 - 9th floor – Pacaembu, 01246000, São Paulo, Brazil
1 shared publication- Fernanda Cristina dos Santos Simeao
Instituto Adolfo Lutz
1 shared publication Fernanda Cristina dos Santos Simeão
Tuberculosis and Mycobacteriosis Branch, Bacteriology Center, Adolfo Lutz Institute, Avenida Doutor Arnaldo, 351 - 9th floor – Pacaembu, 01246000, São Paulo, Brazil
1 shared publicationJuliana Failde Gallo
Tuberculosis and Mycobacteriosis Branch, Bacteriology Center, Adolfo Lutz Institute, Avenida Doutor Arnaldo, 351 - 9th floor – Pacaembu, 01246000, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 15 April 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (4) , 002005
Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024
Introduction. Infections caused by Mycobacterium abscessus, an environmentally prevalent, rapidly growing mycobacteria, are increasingly frequent in developed countries. Objective. To analyse the drug susceptibility profiles of M. abscessus isolated in the state of São Paulo from 2008 to 2024. Methods. Of the 2,402 M. abscessus isolates identified during those 17 years, 558 (23.2%) met the American Thoracic Society’s microbiologic and clinical criteria for drug susceptibility testing (DST), which was performed for five agents – clarithromycin, amikacin, cefoxitin, ciprofloxacin, and doxycycline. Results. Clarithromycin showed a dramatic increase in resistance phenotype from ≤10% in the early period to 73–90% over the last 8 years. Over half those isolates demonstrated inducible resistance. Resistance to amikacin was found in fewer than 5% of isolates from 2016 to 2021. In 2022, that result increased to 13%, but for 2023 and 2024, it had fallen back to 2%. Over the past decade, cefoxitin DST has reported the majority of isolates as intermediate, a problematic result in M. abscessus group (MAG) infections, which typically require long-term treatment for successful outcomes. Since 2018, the annual susceptibility rate has been ≤18%, and in five of the 7 years, ≤7%. Ciprofloxacin was typically assessed as susceptible from 2009 to 2011, then decreased sharply to ≤20% over the next several years, and since 2018, the rate has been less than 5%. Through the entire study, doxycycline resistance has remained consistently high; in the years since 2018, ≤6% of isolates have been susceptible. Conclusion. This study demonstrates wide variation among MAG clinical isolates in the frequency of susceptibility, both across different agents and within individual agents over time. These results emphasize the importance of performing high-quality DST on MAG clinical isolates and suggest the need to consider revising the standard panel of drugs tested.
- 15 April 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (4) , 002005
Open AccessDrug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024
Introduction. Infections caused by Mycobacterium abscessus, an environmentally prevalent, rapidly growing mycobacteria, are increasingly frequent in developed countries. Objective. To analyse the drug susceptibility profiles of M. abscessus isolated in the state of São Paulo from 2008 to 2024. Methods. Of the 2,402 M. abscessus isolates identified during those 17 years, 558 (23.2%) met the American Thoracic Society’s microbiologic and clinical criteria for drug susceptibility testing (DST), which was performed for five agents – clarithromycin, amikacin, cefoxitin, ciprofloxacin, and doxycycline. Results. Clarithromycin showed a dramatic increase in resistance phenotype from ≤10% in the early period to 73–90% over the last 8 years. Over half those isolates demonstrated inducible resistance. Resistance to amikacin was found in fewer than 5% of isolates from 2016 to 2021. In 2022, that result increased to 13%, but for 2023 and 2024, it had fallen back to 2%. Over the past decade, cefoxitin DST has reported the majority of isolates as intermediate, a problematic result in M. abscessus group (MAG) infections, which typically require long-term treatment for successful outcomes. Since 2018, the annual susceptibility rate has been ≤18%, and in five of the 7 years, ≤7%. Ciprofloxacin was typically assessed as susceptible from 2009 to 2011, then decreased sharply to ≤20% over the next several years, and since 2018, the rate has been less than 5%. Through the entire study, doxycycline resistance has remained consistently high; in the years since 2018, ≤6% of isolates have been susceptible. Conclusion. This study demonstrates wide variation among MAG clinical isolates in the frequency of susceptibility, both across different agents and within individual agents over time. These results emphasize the importance of performing high-quality DST on MAG clinical isolates and suggest the need to consider revising the standard panel of drugs tested.
- Open Access
- 16 March 2023
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 72 (3) , 001670
Development of multiplex real-time PCR for detection of clarithromycin resistance genes for the Mycobacterium abscessus group
Introduction. The M. abscessus molecular identification and its drug-resistance profile are important to choose the correct therapy. Aim. This work developed a multiplex real-time PCR (mqPCR) for detection of clarithromycin resistance genes for the Mycobacterium abscessus group. Methodology. Isolates received by Adolfo Lutz Institute from 2010 to 2012, identified by PCR restriction enzyme analysis of a fragment of the hsp65 gene (PRA-hsp65) as M. abscessus type 1 (n=135) and 2 (n=71) were used. Drug susceptibility test (DST) for CLA were performed with reading on days 3 and 14. Subespecies identification by hsp65 and rpoB genes sequencing and erm(41) and rrl genes for mutation detection and primer design were performed. erm(41) gene deletion was detected by conventional PCR. Primers and probes were designed for five detections: erm(41) gene full size and with deletion; erm(41) gene T28 and C28; rrl gene A2058. Results. In total, 191/206 (92.7 %) isolates were concordant by all methods and 13/206 (6.3 %) were concordant only between molecular methods. Two isolates (1.0 %) were discordant by mqPCR compared to rrl gene sequencing. The mqPCR obtained 204/206 (99.0 %) isolates in agreement with the gold standard, with sensitivity and specificity of 98 and 100 %, respectively, considering the gold standard method and 92 and 93 % regarding DST. Conclusion. The mqPCR developed by us proved to be an easy-to-apply tool, minimizing time, errors and contamination.
- 16 March 2023
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 72 (3) , 001670
Open AccessDevelopment of multiplex real-time PCR for detection of clarithromycin resistance genes for the Mycobacterium abscessus group
Introduction. The M. abscessus molecular identification and its drug-resistance profile are important to choose the correct therapy. Aim. This work developed a multiplex real-time PCR (mqPCR) for detection of clarithromycin resistance genes for the Mycobacterium abscessus group. Methodology. Isolates received by Adolfo Lutz Institute from 2010 to 2012, identified by PCR restriction enzyme analysis of a fragment of the hsp65 gene (PRA-hsp65) as M. abscessus type 1 (n=135) and 2 (n=71) were used. Drug susceptibility test (DST) for CLA were performed with reading on days 3 and 14. Subespecies identification by hsp65 and rpoB genes sequencing and erm(41) and rrl genes for mutation detection and primer design were performed. erm(41) gene deletion was detected by conventional PCR. Primers and probes were designed for five detections: erm(41) gene full size and with deletion; erm(41) gene T28 and C28; rrl gene A2058. Results. In total, 191/206 (92.7 %) isolates were concordant by all methods and 13/206 (6.3 %) were concordant only between molecular methods. Two isolates (1.0 %) were discordant by mqPCR compared to rrl gene sequencing. The mqPCR obtained 204/206 (99.0 %) isolates in agreement with the gold standard, with sensitivity and specificity of 98 and 100 %, respectively, considering the gold standard method and 92 and 93 % regarding DST. Conclusion. The mqPCR developed by us proved to be an easy-to-apply tool, minimizing time, errors and contamination.